Compositions and products containing S-equol, and methods...

Details Compositions and products containing S-equol, and methods... Compositions and products containing S-equol, and methods...

2011-06-14

2011-06-14

Chung, Susannah (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C549S399000, C549S408000

Reexamination Certificate

active

07960432

ABSTRACT:
A composition for use in making commercial food and skin products comprising S-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism.

REFERENCES:
patent: 4390559 (1983-06-01), Zilliken
patent: 4814346 (1989-03-01), Albert et al.
patent: 5141746 (1992-08-01), Fleury et al.
patent: RE34457 (1993-11-01), Okamoto et al.
patent: 5352384 (1994-10-01), Shen
patent: 5424331 (1995-06-01), Shlyankevich
patent: 5498631 (1996-03-01), Gorbach et al.
patent: 5523087 (1996-06-01), Shlyankevich
patent: 5726034 (1998-03-01), Bryan et al.
patent: 5733926 (1998-03-01), Gorbach
patent: 5804234 (1998-09-01), Suh et al.
patent: 5830887 (1998-11-01), Kelly
patent: 5849798 (1998-12-01), Charpentier et al.
patent: 5855892 (1999-01-01), Potter et al.
patent: 5942539 (1999-08-01), Hughes, Jr. et al.
patent: 5952374 (1999-09-01), Clarkson, Jr. et al.
patent: 5958946 (1999-09-01), Styczynski et al.
patent: 5990291 (1999-11-01), Waggle et al.
patent: 6004558 (1999-12-01), Thurn et al.
patent: 6020471 (2000-02-01), Johns et al.
patent: 6054636 (2000-04-01), Fader
patent: 6060070 (2000-05-01), Gorbach
patent: 6083526 (2000-07-01), Gorbach
patent: 6146668 (2000-11-01), Kelly et al.
patent: 6159959 (2000-12-01), Miller
patent: 6194450 (2001-02-01), Charpentier et al.
patent: 6242594 (2001-06-01), Kelly
patent: 6258856 (2001-07-01), Chamberlain et al.
patent: 6326366 (2001-12-01), Potter et al.
patent: 6340703 (2002-01-01), Kelly
patent: 6375994 (2002-04-01), Paul et al.
patent: 6455032 (2002-09-01), Kelly et al.
patent: 6497906 (2002-12-01), Kelly
patent: 6509043 (2003-01-01), Høie
patent: 6518301 (2003-02-01), Barlaam et al.
patent: 6544566 (2003-04-01), Waggle et al.
patent: 6562380 (2003-05-01), Kelly
patent: 6565864 (2003-05-01), Pillai et al.
patent: 6599536 (2003-07-01), Kelly et al.
patent: 6638543 (2003-10-01), Kang et al.
patent: 6642212 (2003-11-01), Kelly
patent: 6649648 (2003-11-01), Kelly et al.
patent: 6716424 (2004-04-01), Uchiyama et al.
patent: 7025998 (2006-04-01), Senin et al.
patent: 7396855 (2008-07-01), Setchell et al.
patent: 2002/0001565 (2002-01-01), Shapiro
patent: 2002/0019377 (2002-02-01), Jenkins et al.
patent: 2002/0035074 (2002-03-01), Kelly
patent: 2002/0160064 (2002-10-01), Zulli et al.
patent: 2002/0198248 (2002-12-01), Kelly et al.
patent: 2003/0018060 (2003-01-01), Kelly et al.
patent: 2003/0027772 (2003-02-01), Breton
patent: 2003/0059384 (2003-03-01), Kelly et al.
patent: 2003/0078214 (2003-04-01), Kelly
patent: 2003/0219499 (2003-11-01), Kelly et al.
patent: 2004/0147594 (2004-07-01), Setchell et al.
patent: 2007/0043108 (2007-02-01), Lephart et al.
patent: 2010/0076071 (2010-03-01), Lephart et al.
patent: 2010/0087519 (2010-04-01), Lephart et al.
patent: H02-124883 (1990-05-01), None
patent: WO 93/23069 (1993-11-01), None
patent: WO 94/23716 (1994-10-01), None
patent: WO 96/10341 (1996-04-01), None
patent: WO 97/06273 (1997-02-01), None
patent: 9826784 (1998-06-01), None
patent: WO 98/48790 (1998-11-01), None
patent: 9949851 (1999-10-01), None
patent: 99/61028 (1999-12-01), None
patent: 00/13661 (2000-03-01), None
patent: 00/30663 (2000-06-01), None
patent: 00/41491 (2000-07-01), None
patent: 00/49009 (2000-08-01), None
patent: 00/62765 (2000-10-01), None
patent: 00/62774 (2000-10-01), None
patent: 02/03976 (2002-01-01), None
patent: 02/03977 (2002-01-01), None
patent: 02/03992 (2002-01-01), None
patent: WO 02/11675 (2002-02-01), None
patent: 02/053108 (2002-07-01), None
patent: 02/062367 (2002-08-01), None
patent: WO 02/087517 (2002-11-01), None
patent: WO 02/089757 (2002-11-01), None
patent: WO 2004/022023 (2004-03-01), None
patent: WO 2004/026274 (2004-04-01), None
patent: WO 2004/039327 (2004-05-01), None
Brittain et al, Polymorphism in Pharmaceutical Solids, vol. 95, 1999, 348-361, especially p. 357, second paragraph.
Widyarini et al., Photochemistry and Photobiology, 2001, 74(3), pp. 465-470.
Papers filed in U.S. Appl. No. 11/059,951, “Use of Equol for Treating Skin Diseases,” filed Feb. 17, 2005, Edwin D. Lephart et al., Conf. No. 8332, 60 pages.
Adlercreutz, H., et al., Excretion of The Lignans Enterolactone and Enterodiol and of Equol in Omnivorous and Vegetarian Postmenopausal Women and in Women with Breast Cancer.The Lancet, Dec. 11, 1982, 1295-1299.
Akaza, H., et al., Is Daidzein Non-metabolizer High Risk for Prostate Cancer? A case-controlled Study of Serum Soybean Isoflavone Concentration.Jpn J Clin Oncol, 2002, 32(8): 296-300.
Ingram, D., et al., Case-control study of phyto-oestrogens and breast cancer.The Lancet, Oct. 4, 1997, vol. 350, 990-994.
Kostelac, D., et al., Phytoestrogens Mmodulate Binding Response of Estrogen Receptors α and β to the Estrogen Response Element.Journal of Agricultural and Food Chemistry, 2003, 51(26): 7632.7635.
Lephart, E., Antiaging Effects of Equol: A Unique Antiandrogenic Isoflavone Metabolite and its influence in Stimulating Collagen Deposition in Human Dermal Monolayer Fibroblasts,J Am Acad Dermatol, Mar. 2006, AB103.
Lephart, E.D., Equol: A unique anti-androgenic isofavone metabolite stimulates Collagen (I and III), elastin and human fibroblast proliferation and inhibits matrix metalloproteinases and elastase in 3D cultures via FACS analysis,J Am Acad Dermatol, Mar. 2005, 85.
Lund, T.D., Altered sexually dimorphic nucleus of the preoptic area (SDN-POA) volume in adult Long-Evans rats by dietary soy phytoestrogens;Brain Research, 2001, 914(1-2).
Setchell, D.R., et al., S-Equol, a potent ligand for estrogen receptor β, is the exclusive enantiomeric form of the soy isofavone metabolite produced by human intestinal bacterial flora,The American Journal of Clinical Nutrition, May 2005, 81, 1072-1079.
Weber, K.S., Dietary Soy-phytoestrogens decrease testosterone levels and prostate weight without altering LH, prostate 5α-reductase or testicular steroidogenic acute regulatory peptide levels in adult male Sprague-Dawley rats,Journal of Endocrinology, 2001, 170:591-599.
Office Action dated Mar. 27, 2007 from related U.S. Appl. No. 10/625,989.
Alda, J. et al., Purfication and Chemical Characterization of Potent Inhibitor of the Na—K—CI Cotransport System in Rat Urine,Biochemical and Biophysical Research Communications(1996), vol. 221, pp. 279-285.
Kinjo, J., Phytoestrogens. Japanese Journal of Clinical Medicine, Dec. 2000, 58(12), pp. 2434-2438.
Lund, TD et al., Equol is a Novel Anti-Androgen that Inhibits Prostate Growth and Hormone Feedback, Biol. Reprod., Apr. 2004; 70(4) 1188-95, E-Pub. Dec. 17, 2003.
Atkinson, C. et al, In Vitro Incubation of Human Feces with Daidzein and Antibiotics Suggests Interindividual Differences in the Bacteria Responsible for Equol Production, Amer. Society for Nutritional Sciences, 134:596-599, Mar. 2004.
Setchell, Kenneth, D.R.. et al. Phytoestrogens: The Biochemistry, Physiology, and Implications for Human Health of Soy Isoflavones, Am J. Clin Nutri 1998, pp. 1333S-1346S.
Aldercreutz, H. et al, Determination of Urinary Lignans and Phytoestrogen Metabolites, Potential Antiestrogen and Anticarcinogens in Urine of Women on Various Habitual Diets, J. Steroid Biochem, vol. 25, pp. 791-797 (1996), Abstract.
Thompson, M.A. et al., Characterization of the Estrogenic Properties of A Nonsteroidal Estrogen, Equol, Extracted from Urine of Pregnant Macaques Biol Reprod, Nov. 1984; 31: 705-713.
Hedlund, T.E. et al., Soy Isoflavonoid Equol Modulates the Growth of Benign and Malignant Prostatic Epithelial Cells in Vitro, The Prostate 54:68-78 (2003) accepted May 14, 2002.
Duncan,

Affiliated with

Also associated with

Rating

Compositions and products containing S-equol, and methods... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and products containing S-equol, and methods..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and products containing S-equol, and methods... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2671680